Evidence map›Paper›PMID 41231313›Full record

ArticleAIDS and behavior2026

HIV Pre-Exposure Prophylaxis Service Cascade and Risk Factors Associated with Loss to Follow-Up Among Key Populations in Indonesia: Data from a Real-World Pilot Implementation 2021-2023.

Rudi Wisaksana, Nadia Hanum, Miasari Handayani, Mawar N Pohan, Tarinanda A Putri, Fani F Rakhmat, Zulfan Zazuli, Kusnandar Anggadiredja, Armina Padmasawitri, Dwi S Anggiani and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rudi Wisaksana *Research Center for Care and Control of Infectious Disease, Padjajaran University, Bandung, Indonesia.
Nadia Hanum *Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Jalan Ganesa 10, Bandung, 40132, Indonesia. nadia.hanum@itb.ac.id.ORCID http://orcid.org/0000-0002-9648-5115
Miasari HandayaniResearch Center for Care and Control of Infectious Disease, Padjajaran University, Bandung, Indonesia.
Mawar N PohanResearch Center for Care and Control of Infectious Disease, Padjajaran University, Bandung, Indonesia.
Tarinanda A PutriResearch Center for Care and Control of Infectious Disease, Padjajaran University, Bandung, Indonesia.
Fani F RakhmatResearch Center for Care and Control of Infectious Disease, Padjajaran University, Bandung, Indonesia.
Zulfan ZazuliDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Jalan Ganesa 10, Bandung, 40132, Indonesia.
Kusnandar AnggadiredjaDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Jalan Ganesa 10, Bandung, 40132, Indonesia.
Armina PadmasawitriDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Jalan Ganesa 10, Bandung, 40132, Indonesia.
Dwi S AnggianiHIV and STI Working Group of the Directorate of Disease Prevention and Control, Indonesian Ministry of Health, Jakarta, Indonesia.
Nurhalina AfrianaHIV and STI Working Group of the Directorate of Disease Prevention and Control, Indonesian Ministry of Health, Jakarta, Indonesia.
Endang LukitosariHIV and STI Working Group of the Directorate of Disease Prevention and Control, Indonesian Ministry of Health, Jakarta, Indonesia.
Bagus R PrabowoThe Joint United Nations Programme on HIV/AIDS (UNAIDS) , Jakarta, Indonesia.

Funding

Joint United Nations Programme on HIV/AIDS contract of PR No: 2022/1236445 PO No: 202859205.
6 · The paper itself

Abstract

The pre-exposure prophylaxis (PrEP) care cascade depicting eligibility, initiation, and continuation, as well as loss to follow-up (LTFU) among individuals taking PrEP, has not been systematically evaluated in Indonesia. We examined baseline factors associated with PrEP initiation, the PrEP care cascade, and longitudinal risk factors of LTFU in the Indonesia PrEP Pilot Program, a large-scale implementation program for key populations in Indonesia: men who have sex with men (MSM), female sex workers (FSW), people who inject drugs (PWID), transgender women (TGW), and serodiscordant partners of people living with HIV (SD-PLHIV). Of the 16,469 eligible individuals, 9,124 (55.4%) initiated PrEP (mean age 29.4 [SD 7.5], 85.9% men, 74.4% MSM, 92% from Java-Bali). PrEP initiations were significantly higher among older people, women, FSW and TGW (versus MSM), while markedly lower among PWID and SD-PLHIV and those living in provinces not covered by the program. PrEP continuations at months one and three were very low among FSW (37% and 34%, respectively). The cumulative LTFU rate at 12 months was 41.9% (95% confidence interval [CI], 40.9%-43%). Becoming LTFU was predicted by being younger, being a woman, being an FSW, living in South Sulawesi, West Java, or East Java (versus Jakarta), having no STI diagnoses, reporting consistent condom use, and having high adherence. Our findings revealed gaps in PrEP initiation, continuation, and LTFU among key populations taking PrEP in Indonesia. Targeted interventions are needed to address engagement among those likely to LTFU and populations underserved by the program to improve initiation and continuation.

Indexed as

Anti-HIV AgentsHIV InfectionsLost to Follow-UpPre-Exposure ProphylaxisAdultFemaleHomosexuality, MaleHumansIndonesiaMaleMiddle AgedPilot ProjectsRisk FactorsSexual PartnersSex WorkersTransgender PersonsAnti-HIV AgentsCascadeHIV preventionIndonesiaKey populationsLoss to follow-upPrEP

Identifiers

PMID41231313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.